Macula Edema Clinical Trial
Official title:
Dextenza vs Prednisolone Acetate After Cataract Surgery for Patients With Diabetes
This study aims to compare the effectiveness of Dextenza vs standard of care prednisolone taper after cataract surgery in diabetic patients with regards to controlling post-op inflammation at post-op days 7, 14, and 30.
The inflammation after cataract surgery is controlled at the investigators' institution by a taper of prednisolone acetate 1%, which consists of four drops daily for one week, followed by three drops daily for one week, then two drops daily for one week, then one drop daily for one week. Due to the frequency of drops needed after cataract surgery, compliance with the post-op regimen often wavers. This study aims to evaluate the efficacy of Dextenza, which has been shown to be better than placebo after cataract surgery (1), against prednisolone acetate taper. If shown to be as effective without compromising safety, it could be a very convenient alternative to prednisolone acetate taper. Furthermore, if Dextenza is shown to be as effective as prednisolone taper in diabetic patients, it could be logically generalized that it would be effective in patients without diabetes as well, as patients without diabetes (and with no confounding risk factors, such as a history of uveitis) are less prone to developing post-op macular edema. Risks are minimal for this FDA approved treatment and include iridocyclitis (10%); intraocular pressure increased (6%); visual acuity reduced (2%); cystoid macular edema (1%); corneal edema (1%); eye pain (1%) and conjunctival hyperemia (1%). These risks are comparable to prednisolone acetate. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04703231 -
Comparison of Ocular Findings in Patients Between Surgical and Natural Menopause
|
||
Completed |
NCT03321253 -
Changes of Macular Pigment and Parameters of Eyes After YAG Laser Treatment in Cases With Capsule Opacification
|
N/A | |
Recruiting |
NCT04775849 -
Intraoperative Berger Space Imaging (IBSI)
|
N/A | |
Active, not recruiting |
NCT04120636 -
Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
|
Phase 1 | |
Recruiting |
NCT05122702 -
An Innovative Chinese Herbal Formula for Macular Edema
|
Phase 2 | |
Completed |
NCT03363295 -
Evaluation of Macular Changes After Intracameral Moxifloxacin for Prevention of Endophthalmitis
|
Phase 4 | |
Completed |
NCT04359771 -
Transfoveal Micropulse Laser for Center Involving Diabetic Macular Edema
|
Phase 4 | |
Completed |
NCT05385562 -
Formulated PSTA Injection Versus PATA Alone in the Management of Macular Edema Secondary to Non-ischemic Retinal Vein Occlusions
|
N/A | |
Recruiting |
NCT04847869 -
Near-Infrared Light Photobiomodulation Treatment for Retinal Vein Occlusion Macular Oedema
|
N/A | |
Completed |
NCT03093701 -
TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)
|
Phase 2 |